1
A Pilot Study of the Immunomodulatory Agent Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
Condition(s):Kidney CancerLast Updated:August 4, 2022Not yet recruiting
ACARBOSE: 114 Clinical Trials, Page 1 of 12
Hide Studies Not Open or Pending
2
Study of Acarbose in Longevity
Condition(s):AgingLast Updated:January 26, 2022Completed
3
Acarbose, Postprandial Hypotension and Type 2 Diabetes
Condition(s):Type 2 Diabetes; Postprandial HypotensionLast Updated:June 28, 2017Completed
4
Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)
Condition(s):AgingLast Updated:March 14, 2019Completed
5
Acarbose and Older Adults With Postprandial Hypotension
Condition(s):Other Specified Hypotension; SyncopeLast Updated:May 28, 2021Completed
6
Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)
Condition(s):PCOLast Updated:January 6, 2012Completed
7
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Condition(s):Type 2 Diabetes MellitusLast Updated:August 17, 2020Completed
8
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
Condition(s):Diabetes MellitusLast Updated:August 25, 2010Completed
9
Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients
Condition(s):Glucose Intolerance; Postprandial Hyperglycemia; Cardiovascular Risk FactorLast Updated:February 9, 2015Completed
10
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients
Condition(s):Endothelial Function; Type 2 Diabetes; Gemigliptin; AcarboseLast Updated:July 16, 2015Unknown status